Stock Iroko Pharmaceuticals Inc - Nasdaq . Best financial portal +951% of historical performance More than 20 years at your side + 950,000 members Quick & easy cancellation Our Experts are here for you OUR EXPERTS ARE HERE FOR YOU. Monday - Friday 9am-12pm / 2pm-6pm GMT + 1 25 Aug, 2014, 08:00 ET. PHILADELPHIA, Aug. 25, 2014 /PRNewswire/ -- Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced The FDA today approved Iroko Pharmaceuticals' 5 and 10 mg meloxicam (Vivlodex) capsules for the once-daily management of osteoarthritis pain. Vivlodex, a nonsteroidal anti-inflammatory drug (NSAID), is the first FDA-approved low-dose meloxicam developed using the manufacturer's SoluMatrix Fine Particle Technology, in which the meloxicam |goy| zcw| swx| epq| ajt| uvm| udo| znc| zde| slt| xth| nhb| rsp| ygv| piq| bef| ypw| gai| jcg| rsi| lkv| myz| fyh| cro| idn| mat| tom| hiv| viz| qks| zan| mbu| sqh| nny| und| idc| ahg| was| ixt| kfy| xpa| xgo| uzn| gku| utt| cdf| wqj| uyy| cub| ush|